China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized, double-blind, placebo-controlled Phase III GLORY-1 study for its mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. The drug is being evaluated for the treatment of overweight or obese Chinese patients, marking a significant step in addressing obesity through innovative therapeutics.
Study Design and Objectives
The GLORY-1 study is designed to assess the efficacy and safety of mazdutide in overweight or obese Chinese participants. It is recognized as the first regulatory study for a GLP-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist in obesity globally. The study plans to enroll a total of 600 subjects, who will be randomly assigned to receive either mazdutide 4mg, mazdutide 6mg, or a placebo at a ratio of 1:1:1 for 48 weeks of treatment.
Partnership and Drug Profile
Innovent previously entered into a licensing agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3, also known as mazdutide (IBI362) or LY3305677, in China. Mazdutide is a long-acting synthetic peptide related to mammalian oxyntomodulin (OXM). It incorporates a fatty acid side chain to extend its duration of action, enabling once-weekly administration. Mazdutide is believed to activate both GLP-1 and glucagon receptors in humans, improving glucose tolerance and inducing weight loss by mimicking the effects of endogenous oxyntomodulin.-Fineline Info & Tech
